These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 536573)

  • 1. [Clinical value of electroretinographic tests in Parkinson's disease (author's transl)].
    Cavallacci G; Perossini M
    J Fr Ophtalmol; 1979 Dec; 2(12):705-8. PubMed ID: 536573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The electroretinogram and visual evoked potentials in patients with Parkinson's disease].
    Burguera JA; Vilela C; Traba A; Ameave Y; Vallet M
    Arch Neurobiol (Madr); 1990; 53(1):1-7. PubMed ID: 2393335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symposium on levodopa in Parkinson's disease. Clinical and pharmacological aspects. Where do we go from here?
    Clin Pharmacol Ther; 1971; 12(2):408-16. PubMed ID: 5577487
    [No Abstract]   [Full Text] [Related]  

  • 4. [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].
    Pletscher A; Bartholini G; Gey KF; Jenni A
    Schweiz Med Wochenschr; 1970 May; 100(19):797-804. PubMed ID: 4924275
    [No Abstract]   [Full Text] [Related]  

  • 5. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

  • 7. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of psychometic tests in 23 patients with Parkinson's disease after 6 months treatment with L-dopa].
    Barbizet J; Duizabo P; Pasquier M
    Rev Neurol (Paris); 1972 Aug; 127(2):311-3. PubMed ID: 4666638
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anticholinergic treatment of Parkinson's disease (author's transl)].
    Ascher PW
    Wien Klin Wochenschr; 1976 Oct; 88(19):641-6. PubMed ID: 790774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I
    J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008
    [No Abstract]   [Full Text] [Related]  

  • 11. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
    Marjerrison G; Boulton AA; Rajput AH
    Dis Nerv Syst; 1972 Mar; 33(3):164-9. PubMed ID: 5022451
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].
    Morselli PL; Rizzo M; Tognoni G
    Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589
    [No Abstract]   [Full Text] [Related]  

  • 15. [Parkinson's disease, dysautonomy, and auto-antibodies directed against sympathetic neurones (author's transl)].
    Emile J; Pouplard A; Bossu Van Nieuwenhuyse C; Bernat-Viallet C
    Rev Neurol (Paris); 1980; 136(3):221-33. PubMed ID: 7414148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Subclinical vestibular abnormalities in Parkinson's disease (author's transl)].
    Stamboulis E; Tsakanikas C; Scarpalezos S
    Rev Neurol (Paris); 1981; 137(3):211-6. PubMed ID: 6973182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
    Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts in the management of Parkinson's disease.
    Chapman WG
    West Indian Med J; 1974 Mar; 23(1):61-4. PubMed ID: 4456821
    [No Abstract]   [Full Text] [Related]  

  • 19. [Salsolinol, an endogenous molecule. Possible implications in alcoholism, Parkinson's disease and pain].
    Vernay D; Eschalier A; Durif F; Aumaitre O; Rigal B; Ben Sadoun A; Fialip J; Marty H; Philip E; Bougerolle AM
    Encephale; 1989; 15(6):511-6. PubMed ID: 2515055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial of Sinemet CR4 in patients with Parkinson's disease.
    Anderson TJ; Ewer TC; Gilchrist NL; Donaldson IM
    N Z Med J; 1992 Mar; 105(929):81-2. PubMed ID: 1545941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.